These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Aerosol therapy with colistin methanesulfonate: a biopharmaceutical issue illustrated in rats. Marchand S; Gobin P; Brillault J; Baptista S; Adier C; Olivier JC; Mimoz O; Couet W Antimicrob Agents Chemother; 2010 Sep; 54(9):3702-7. PubMed ID: 20547787 [TBL] [Abstract][Full Text] [Related]
8. Disposition of instilled versus nebulized tobramycin and imipenem in ventilated intensive care unit (ICU) patients. Badia JR; Soy D; Adrover M; Ferrer M; Sarasa M; Alarcón A; Codina C; Torres A J Antimicrob Chemother; 2004 Aug; 54(2):508-14. PubMed ID: 15215224 [TBL] [Abstract][Full Text] [Related]
10. Preclinical Pharmacokinetic and Pharmacodynamic Data To Support Cefoxitin Nebulization for the Treatment of Mycobacterium abscessus. Mehta S; Aranzana-Climent V; Rammaert B; Grégoire N; Marchand S; Couet W; Buyck JM Antimicrob Agents Chemother; 2019 Jul; 63(7):. PubMed ID: 31061149 [No Abstract] [Full Text] [Related]
11. Comparative lung distribution of radiolabeled tobramycin between nebulized and intravenous administration in a mechanically-ventilated ovine model, an observational study. Dhanani JA; Goodman S; Ahern B; Cohen J; Fraser JF; Barnett A; Diab S; Bhatt M; Roberts JA Int J Antimicrob Agents; 2021 Feb; 57(2):106232. PubMed ID: 33232733 [TBL] [Abstract][Full Text] [Related]
12. A pharmacokinetics and safety comparison of a highly concentrated tobramycin solution with TOBI. Griese M; Eismann C; Börner G; Denk O; Schierholz JM; Keller M; Mazurek H; Kappler M J Aerosol Med Pulm Drug Deliv; 2014 Jun; 27(3):185-92. PubMed ID: 23789705 [TBL] [Abstract][Full Text] [Related]
13. Solid lipid nanoparticles (SLN) as ocular delivery system for tobramycin. Cavalli R; Gasco MR; Chetoni P; Burgalassi S; Saettone MF Int J Pharm; 2002 May; 238(1-2):241-5. PubMed ID: 11996827 [TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics and safety of tobramycin administered by the PARI eFlow rapid nebulizer in cystic fibrosis. Hubert D; Leroy S; Nove-Josserand R; Murris-Espin M; Mely L; Dominique S; Delaisi B; Kho P; Kovarik JM J Cyst Fibros; 2009 Sep; 8(5):332-7. PubMed ID: 19651542 [TBL] [Abstract][Full Text] [Related]
15. Transmucosal transport of tobramycin incorporated in SLN after duodenal administration to rats. Part I--a pharmacokinetic study. Cavalli R; Zara GP; Caputo O; Bargoni A; Fundarò A; Gasco MR Pharmacol Res; 2000 Dec; 42(6):541-5. PubMed ID: 11058406 [TBL] [Abstract][Full Text] [Related]
17. Basis for nebulized antibiotics: droplet characterization and in vitro antimicrobial activity versus Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa. Todisco T; Eslami A; Baglioni S; Sposini T; Tascini C; Sommer E; Knoch M J Aerosol Med; 2000; 13(1):11-6. PubMed ID: 10947319 [TBL] [Abstract][Full Text] [Related]
18. In vivo efficacy of humanised intermittent versus continuous ceftazidime in combination with tobramycin in an experimental model of pseudomonal pneumonia. Croisier D; Martha B; Piroth L; Chavanet P Int J Antimicrob Agents; 2008 Dec; 32(6):494-8. PubMed ID: 18804348 [TBL] [Abstract][Full Text] [Related]
19. Bismuth-thiol incorporation enhances biological activities of liposomal tobramycin against bacterial biofilm and quorum sensing molecules production by Pseudomonas aeruginosa. Halwani M; Hebert S; Suntres ZE; Lafrenie RM; Azghani AO; Omri A Int J Pharm; 2009 May; 373(1-2):141-6. PubMed ID: 19429299 [TBL] [Abstract][Full Text] [Related]
20. The penetration of aminoglycosides into the alveolar lining fluid of rats. The effect of airway inflammation. Valcke Y; Pauwels R; Van der Straeten M Am Rev Respir Dis; 1990 Nov; 142(5):1099-103. PubMed ID: 2240833 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]